anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Quetiapine Fumarate
Trial phase: Phase 3
SMILES: O=C(O)C=CC(=O)O.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1.OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Seroquel XR, flexible dose and assigned ADT

Seroquel XR: tablet/capsule
Eligibility criteria:
Inclusion Criteria:

Male and female outpatients 18 to 65 years of age, inclusive, at the time of informed consent.
Subjects with both a diagnosis of MDD, and in a current major depressive episode, as defined by DSM-IV-TR criteria
Subjects willing to discontinue all prohibited psychotropic medications to meet protocol-required washouts prior to and during the trial period.

Exclusion Criteria:

Females who are breast-feeding and/or who have a positive pregnancy test result during screening prior to receiving trial medication
Subject has a current Axis I (DSM-IV-TR) diagnosis of: dementia, Schizophrenia, Bipolar, Eating disorder , Obsessive-compulsive disorder, Panic disorder, Posttraumatic stress disorder
Subjects experiencing hallucinations, delusions or any psychotic symptomatology in the current major depressive episode.
Subjects who have met DSM-IV-TR criteria for substance abuse or dependence within the past 180 days
Subjects currently treated with insulin for diabetes.
Subjects with uncontrolled hypertension
Subjects with known ischemic heart disease or history of myocardial infarction, congestive heart failure, angioplasty, stenting, or coronary artery bypass Surgery
Subjects with a positive drug screen for cocaine, marijuana, or other illicit drugs
Inability to swallow tablets or tolerate oral medication
Abnormal laboratory test results, vital signs and ECG results
Subjects who previously participated in any prior brexpiprazole clinical trial.
Intervention: Oxygen
Trial phase: Phase 4
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 10
Group description: Participants ages 1-6 years old received IV vancomycin, or semi-synthetic penicillin, or first-generation cephalosporins, clindamycin; given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
Eligibility criteria:
Inclusion Criteria:

To be included in this study, participants must:

Sign a parental consent form; if appropriate, sign an assent form
Be between 1 and 17 years of age
Have proven or probable bacteremia caused by S. aureus based on the traditional culture result, rapid diagnostic test or Gram stain
If female of childbearing potential, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study
If male, must take appropriate measures to not get partner pregnant
Able to comply with the protocol requirements

Exclusion Criteria:

Participants will not be allowed into the study if they:

Have received a certain amount of antibacterial therapy specific for current bacteremia unless it is demonstrated that the organism is resistant to the given antibacterial;
Anticipate to require other antibiotics that may be potentially effective against S. aureus;
Have shock or hypotension unresponsive to standard therapy;
Have received an investigational product or have participated in an experimental procedure within 30 days;
Have an intolerance or hypersensitivity to daptomycin;
Have renal insufficiency;
Have prior history or current evidence of muscle damage (rhabdomyolysis; significant CPK elevation);
Have history of clinically significant muscular disease, nervous system or seizure disorder, including unexplained muscular weakness, history of peripheral neuropathy, Guillain-Barré or spinal cord injury;
Have S. aureus pneumonia, empyema, meningitis, or endocarditis
Intervention: Oxygen
Trial phase: Phase 4
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 9
Group description: Participants ages 7-11 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-28 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
Eligibility criteria:
Inclusion Criteria:

To be included in this study, participants must:

Sign a parental consent form; if appropriate, sign an assent form
Be between 1 and 17 years of age
Have proven or probable bacteremia caused by S. aureus based on the traditional culture result, rapid diagnostic test or Gram stain
If female of childbearing potential, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study
If male, must take appropriate measures to not get partner pregnant
Able to comply with the protocol requirements

Exclusion Criteria:

Participants will not be allowed into the study if they:

Have received a certain amount of antibacterial therapy specific for current bacteremia unless it is demonstrated that the organism is resistant to the given antibacterial;
Anticipate to require other antibiotics that may be potentially effective against S. aureus;
Have shock or hypotension unresponsive to standard therapy;
Have received an investigational product or have participated in an experimental procedure within 30 days;
Have an intolerance or hypersensitivity to daptomycin;
Have renal insufficiency;
Have prior history or current evidence of muscle damage (rhabdomyolysis; significant CPK elevation);
Have history of clinically significant muscular disease, nervous system or seizure disorder, including unexplained muscular weakness, history of peripheral neuropathy, Guillain-Barré or spinal cord injury;
Have S. aureus pneumonia, empyema, meningitis, or endocarditis
Intervention: Oxygen
Trial phase: Phase 4
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 7
Group description: Participants ages 12-17 years old received IV vancomycin or semi-synthetic penicillin or first-generation cephalosporins or clindamycin, given as per local guidelines or site-specific prescribing information; therapy duration (uncomplicated bacteremia) = 5-28 days, therapy duration (complicated bacteremia) = 7-42 days. IV comparator and subsequent oral therapy were at the discretion of the investigator.
Eligibility criteria:
Inclusion Criteria:

To be included in this study, participants must:

Sign a parental consent form; if appropriate, sign an assent form
Be between 1 and 17 years of age
Have proven or probable bacteremia caused by S. aureus based on the traditional culture result, rapid diagnostic test or Gram stain
If female of childbearing potential, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study
If male, must take appropriate measures to not get partner pregnant
Able to comply with the protocol requirements

Exclusion Criteria:

Participants will not be allowed into the study if they:

Have received a certain amount of antibacterial therapy specific for current bacteremia unless it is demonstrated that the organism is resistant to the given antibacterial;
Anticipate to require other antibiotics that may be potentially effective against S. aureus;
Have shock or hypotension unresponsive to standard therapy;
Have received an investigational product or have participated in an experimental procedure within 30 days;
Have an intolerance or hypersensitivity to daptomycin;
Have renal insufficiency;
Have prior history or current evidence of muscle damage (rhabdomyolysis; significant CPK elevation);
Have history of clinically significant muscular disease, nervous system or seizure disorder, including unexplained muscular weakness, history of peripheral neuropathy, Guillain-Barré or spinal cord injury;
Have S. aureus pneumonia, empyema, meningitis, or endocarditis
Intervention: Misoprostol
Trial phase: Phase 4
ATC code: A02BB01 | G02AD06 | M01AE56
SMILES: CCCCC(C)(O)C/C=C/[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC
Sex: Female
Age groups: Child | Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 123
Group description: women with risk factors for uterine atony who underwent cesarean delivery were assigned randomly to either 400 mcg misoprostol (n=60) or placebo (n=60) placed in buccal space after umbilical cord clamping. The primary outcome variables were the need for additional uterotonic agents, estimated blood loss and uterine atony.

Misoprostol
Eligibility criteria:
Inclusion Criteria:

Women who underwent delivery either by elective or emergent cesarean section at 24 week gestation or later with preoperative levels of hemoglobin and hematocrit determined up to 72 hours prior to delivery. The patients must have at least one of the risk factors for uterine atony listed below:

Fetal macrosomia (estimated fetal weight ≥ 4 Kilos) diagnosed by clinical measurement (Johnson´s technique) or ultrasound measurement (Hadlock´s formula).
Polyhydramnios (defined as Phelan´s amniotic fluid index > 24 cm)
Twin or Multiple pregnancy.
Prolonged labour (prolonged active phase > 12 hours) or precipitate labour(cervical dilatation ≥ 10 cm/hour).
Magnesium sulphate or any other tocolytic agent therapy for ≥ 8 hours before cesarean section.
Intravenous oxytocin therapy for at least 4 hours before cesarean section.
Multiparous women (≥ 3 prior abdominal or vaginal deliveries )
Clinical chorioamnionitis was defined as maternal temperature of ≥ 38°C in addition to more than one of the following criteria: fetal tachycardia (> 160 beats per minute), maternal tachycardia (>100 beats per minute, maternal leukocytosis (15,000 cells/mm3), uterine tenderness or foul smelling amniotic fluid.
Known myomatosis, uterine Müllerian malformations or those diagnosed by ultrasound.

Exclusion Criteria:

Misoprostol incorrect administration
Severe allergic, bleeding disorders (e.g., haemophilia); severe asthma or any other absolute contraindication to misoprostol use.
Any bleeding occurred before delivery (abruptio placentae, placenta praevia) or bleeding due to other causes different than uterine atony.
Intervention: Gemfibrozil
Trial phase: Phase 1
ATC code: C10AB04
SMILES: Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Single oral dose of 600 mg gemfibrozil on Day 1.
Eligibility criteria:
Inclusion Criteria:

Healthy participants as determined by medical history and physical examination
Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

Exclusion Criteria:

Have known allergies to evacetrapib and gemfibrozil, related compounds or any components of the formulation
Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Currently smoke cigarettes or use tobacco or nicotine substitutes
Intervention: Evacetrapib
Trial phase: Phase 1
SMILES: Cc1cc(C)c2c(c1)[C@@H](N(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)CCCN2C[C@H]1CC[C@H](C(=O)O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 24
Group description: Oral doses of 130 mg evacetrapib QD for 10 days (Day 2 through Day 12).
Eligibility criteria:
Inclusion Criteria:

Healthy participants as determined by medical history and physical examination
Have a body mass index of 18 to 32 kilograms per square meter (kg/m^2)

Exclusion Criteria:

Have known allergies to evacetrapib and gemfibrozil, related compounds or any components of the formulation
Have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
Currently smoke cigarettes or use tobacco or nicotine substitutes
Intervention: Bupropion Hydrochloride
Trial phase: Phase 4
SMILES: CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 15
Group description: Participants will receive bupropion XL for 8 weeks.

Bupropion XL for Major Depressive Episode: Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
Eligibility criteria:
Inclusion Criteria:

Patient suffering from an episode of major depressive disorder (MDD)
Age range 18-65 years
History of a past suicide attempt or score > 2 on HDRS item #3 (suicide) at in-person screening interview. Patients with suicidal plan or intent will only be enrolled as inpatients if independent inpatient treatment team agrees with the plan to enroll the patient.
Patients 60 years of age and older must score at least 25 on MMSE at screening.
Patients 60 years of age and older must have a normal ECG within the past year.

Exclusion Criteria:

Bipolar disorder; current psychotic symptoms; bulimia or anorexia that is current or within the past year, or current purging at least twice a week for three months; persons already taking SSRIs or bupropion for other indications (such as anxiety disorders).
Primary disorder is an anxiety disorder such as Panic disorder/GAD/OCD/ Social anxiety disorder, with secondary depression.
Drug or alcohol dependence within past six months; persons with current drug or alcohol abuse may be enrolled if this is assessed as being of lesser importance than the major depressive episode.
Blood pressure reading ≥ 140/90
Active and/or unstable medical problems including a significant risk for seizures
Antipsychotic medication required
Patients who have become hypomanic or manic on antidepressants
Contraindication to the use of an SSRI or bupropion, or currently using Zyban. Anorexia nervosa in remission at least one year is not an exclusion.
Failure to respond to adequate trials of 3 SSRIs or paroxetine or bupropion in the last 2 years (failure to respond to therapeutic trial defined as: at least 2/3 maximal PDR dose for at least 6 weeks).
Lacks capacity to consent
Pregnancy, lactation, or plans to conceive during the course of study participation.
Patients currently on effective treatment, who require adjunctive antipsychotic or mood stabilizing medication, or who are unlikely to respond to single agent treatment for depression will be excluded.
Patients with ferrous metal implants in their bodies, or a history of claustrophobia that precludes MRI, will be excluded.
Patients assessed as being unlikely to tolerate the maximum 2-week delay to start of treatment.
Intervention: BEMPEDOIC ACID
Trial phase: Phase 2
ATC code: C10AX15 | C10BA10
SMILES: CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 37
Group description: Participants initially received ETC-1002 60 milligrams (mg) once daily (QD) on Day 1 for 2 weeks, and then were titrated successively to 120 mg QD for 2 weeks, 180 mg QD for 2 weeks, and 240 mg QD for 2 weeks.
Eligibility criteria:
Key Inclusion Criteria:

A history of statin intolerance that began during statin treatment and resolved within 4 weeks of stopping the statin treatment
For participants on current lipid-regulating drugs - LDL-C 100-220 milligrams per deciliter (mg/dL) and triglycerides <350 mg/dL (prior to wash-out of all lipid-regulating drugs and supplements)
For participants not on current lipid-regulating drugs - LDL-C 115-270 mg/dL and fasting TG <400 mg/dL

Key Exclusion Criteria:

Acute significant cardiovascular disease
Poorly controlled hypertension
Intervention: (18F)fluoroethyltyrosine
Trial phase: Phase 2
SMILES: NC(Cc1ccc(OCCF)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Recurrent GBM patients receiving Avastin, imaged twice with 18F-FET PET before and approximately 8 weeks after receiving Avastin

18F-FET: Radiotracer, surrogate marker for protein synthesis
Eligibility criteria:
Inclusion Criteria:

1. GBM patients with changes on MRI suggestive of recurrence who have not yet initiated antiangiogenic therapy. 2. Age ≥ 18 3. Anticipated survival >3 months 4. Able to give informed consent 5. Capable of undergoing scan without the need for sedation or general anesthesia.

Exclusion Criteria:

Active intracranial infection or nonglial brain mass.
Recent large intracranial hemorrhage (<1 month; size to be determined by principal investigator)
Pregnant or nursing. Quantitative serum hCG testing will be performed prior to the initial and each -subsequent FET- PET scan on all females of childbearing potential. Our BWH Radiation Safety Committee and Partners IRB requires stat serum ß-hcG pregnancy tests.

Patient lives too far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

-
Intervention: Paclitaxel
Trial phase: Phase 1 | Phase 2
ATC code: L01CD01 | L01CD51
SMILES: CC(=O)OC1C(=O)C2(C)C(O)CC3OCC3(OC(C)=O)C2C(OC(=O)c2ccccc2)C2(O)CC(OC(=O)C(O)C(NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: NAB-PACLITAXEL PLUS CARBOPLATIN WITH CONCURRENT RADIATION THERAPY nab-Paclitaxel 50 mg/m2 IV/30min/wk x6 wks

Carboplatin AUC **2 IV/30 min/wk x6wks XRT 6000 cGy
Eligibility criteria:
Inclusion Criteria:

Histologically or cytologically documented NSCLC; Patients must be M0. Patients with T1-T2 with N2 or T3N1-2 are eligible, if inoperable. Patients with T4 with any N or any T with N2 or N3 disease are eligible if unresectable.
Patients with tumors adjacent to a vertebral body are eligible as long as all gross disease can be encompassed in the radiation boost field. The boost volume must be limited to < 50% of the ipsilateral lung volume.
Patients with Zubrod performance status 0-1
Adequate hematologic function
FEV1 with ≥ 1200 cc or ≥ 50% predicted

Exclusion Criteria:

Prior systemic chemotherapy (for lung cancer) and/or thoracic/neck radiotherapy for any reason and/or surgical resection of present cancer
Exudative, bloody, or cytologically malignant effusions
Prior therapy with any molecular targeted drugs (for lung cancer)
Active pulmonary infection not responsive to conventional antibiotics
Clinically significant cardiovascular event (e.g. myocardial infarction, superior vena cava syndrome (SVC), New York Heart Association (NYHA) classification of heart disease >2 (see Appendix B) within 3 months before entry; or presence of cardiac disease that, in the opinion of the Investigator, increases the risk of ventricular arrhythmia.
Patients with > grade 1 neuropathy
Intervention: Diphenhydramine
Trial phase: Not Applicable
ATC code: D04AA32 | D04AA33 | R06AA02 | R06AA52
SMILES: CN(C)CCOC(c1ccccc1)c1ccccc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Increments of 25 mcg to maximum of 3 times (total 75 mcg)

Diphenhydramine
Eligibility criteria:
Inclusion Criteria:

Patients >18 years-old who are undergoing elective colonoscopy with conscious sedation

Exclusion Criteria:

allergy or prior adverse reactions to diphenhydramine
medical contraindications to use of diphenhydramine (e.g. closed angle glaucoma)
pregnancy
Intervention: Dexmedetomidine
Trial phase: Phase 4
ATC code: N05CM18
SMILES: Cc1cccc([C@H](C)c2c[nH]cn2)c1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 71
Group description: We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously, for 10 min) at time of muscle layer closing.
Eligibility criteria:
Inclusion Criteria:

ASA physical status 1 or 2 patients patients scheduled for thyroidectomy

Exclusion Criteria:

Severe cardiovascular disease history of motion sickness active status of upper respiratory infection allergy to dexmedetomidine patients who cannot understand Korean
Intervention: Oxygen
Trial phase: Not Applicable
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2853
Group description: Inspired oxygen will be maintained at 30%.

30% oxygen: Inspired oxygen will be maintained at 30%.
Eligibility criteria:
Inclusion Criteria:

adult colorectal surgical patients
Intervention: Oxygen
Trial phase: Not Applicable
ATC code: V03AN01
SMILES: O=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2896
Group description: Inspired oxygen will be maintained at 80%.

80% oxygen: Inspired oxygen will be maintained at 30%.
Eligibility criteria:
Inclusion Criteria:

adult colorectal surgical patients
Intervention: Regadenoson
Trial phase: Phase 4
ATC code: C01EB21
SMILES: CNC(=O)c1cnn(-c2nc(N)c3ncn([C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)c3n2)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 16
Group description: All patients will undergo PET-MR myocardial perfusion imaging during rapid intravenous administration of 0.4 mg regadenoson.

Regadenoson: Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
Eligibility criteria:
Inclusion Criteria:

Patients who have had a clinically ordered rest/regadenoson single-isotope SPECT-MPI study within 10 days prior to cardiac PET-MRI examination
Reversible perfusion abnormalities on SPECT imaging in at least 2 contiguous myocardial segments
Patients for whom standard of care coronary ICA is planned

Exclusion Criteria:

An clinical event (ie; worsening angina pectoris or myocardial infarction) occuring after the SPECT-MPI and before the cardiac MRI examination
Myocardial revascularization occuring after the SPECT-MPI and before the cardiac MRI examination
Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, etc.)
Renal insufficiency (GFR < 60 mL/min/1.73m2)
Allergy or other contraindication to gadolinium-based MR contrast agent
Second or third degree atrioventricular (AV) block
Active asthma
Seizures
Current hypotension (<100/60)
Current hypertension (>160/90)
Pregnancy
Breast feeding
Use of caffeine, nicotine or over the counter cold medicines within 12 hours of the cardiac PET-MRI examination
Use of the medication dipyridamole within 48 hrs of the cardiac PET-MRI examination
Intervention: Epothilone D
Trial phase: Phase 1 | Phase 2
SMILES: [H][C@@]1(/C(C)=C/c2csc(C)n2)C/C=C(/C)CCC[C@H](C)[C@H](O)[C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 117
Group description: 20,000 unit per day of EPO, Intravenous infusion for three sequential days.

Recombinant human erythropoietin (EPO): 4000 units per vial
Eligibility criteria:
Inclusion Criteria:

Having indirect traumatic optic neuropathy, not more than 3 weeks between trauma and treatment, normal fundoscopy

Exclusion Criteria:

Having other injuries that effect on visual function, direct optic neuropathy, glaucoma, diabetic retinopathy, uncontrolled hypertension, polycythemia, creatinin more than 3 mg/dl, sensitivity to EPO, hyperkalemia, women who use contraceptive pill, pregnant and breast feeding women, history of stroke and cardiovascular diseases, having malignancy